Purpose of the study: Intramuscular injection of the botulinum toxin into the psoas can be proposed for permanent hip flexion due to spastic disorders. Several approaches have been described: retrograde subinguinal, anterolateral suprailiac, and posterior. Ultrasound or computed tomography can be used to guide needle position. These approaches are however limited to access to the L4 region, i.e. far from the motor points and with the risk of injury to the ureter. The purpose of this work was to determine the innervations of the psoas muscle that would be best adapted to this type of injection and thus to describe the most effective and reliable approach.

Material and methods: This anatomy study included 20 dissections to: describe vertebral insertions of the psoas major and the psoas minor and to measure their distance from the iliac crest; define the region where the ureter crosses in front of the psoas.

Results: More than 80% of the psoas muscles presented a proximal insertion on the transverse process of T12 and the body of L1; the mean length of the psoas in the adult is 27 cm above the inguinal ligament; the nerve roots collateral to the lumbar plexus are: 33% L2, 25% L3, 19% L1, 9% L4, 3% L5 and 1% T12, the remainder arising directly from the femoral nerve; the L2-L3 region is situated 4.6 cm on average above the iliac crest.

Discussion: The region facing the L2-L3 space enables access to more than 50% of the psoas nerve branches. Injection via a posterior approach situated in adults 4.6 cm above the iliac crest and identified fluoroscopically is the most reliable access. This will avoid injury to the ureter which lies lower.

Conclusion: This anatomy study described a new more effective less dangerous approach for botulinum toxin injections into the psoas muscle.

We describe the application of a non-invasive extendible endoprosthetic replacement in skeletally-mature patients undergoing revision for failed joint replacement with resultant limb-length inequality after malignant or non-malignant disease. This prosthesis was developed for tumour surgery in skeletally-immature patients but has now been adapted for use in revision procedures to reconstruct the joint or facilitate an arthrodesis, replace bony defects and allow limb length to be restored gradually in the post-operative period.

We record the short-term results in nine patients who have had this procedure after multiple previous reconstructive operations. In six, the initial reconstruction had been performed with either allograft or endoprosthetic replacement for neoplastic disease and in three for non-neoplastic disease. The essential components of the prosthesis are a magnetic disc, a gearbox and a drive screw which allows painless lengthening of the prosthesis using the principle of electromagnetic induction. The mean age of the patients was 37 years (18 to 68) with a mean follow-up of 34 months (12 to 62). They had previously undergone a mean of six (2 to 14) open procedures on the affected limb before revision with the non-invasive extendible endoprosthesis.

The mean length gained was 56 mm (19 to 107) requiring a mean of nine (3 to 20) lengthening episodes performed in the outpatient department. There was one case of recurrent infection after revision of a previously infected implant and one fracture of the prosthesis after a fall. No amputations were performed. Planned exchange of the prosthesis was required in three patients after attainment of the maximum lengthening capacity of the implant. There was no failure of the lengthening mechanism. The Mean Musculoskeletal Tumour Society rating score was 22 of 30 available points (18 to 28).

The use of a non-invasive extendible endoprosthesis in this manner provided patients with good functional results and restoration of leg-length equality, without the need for multiple open lengthening procedures.